DealBio
All collections

Investor Intelligence

9 European Healthtech Investors Active in France

Investors with relevant activity across digital health, diagnostics, medtech, therapeutics and clinical software in France.

Published
  • France
  • Healthtech
  • Digital Health
  • Medtech
  • Biotech

France’s healthtech market is financed by a mix of specialist life-sciences funds, generalist technology investors, public capital and impact investors. Recent deals span prenatal imaging, molecular diagnostics, , digital therapeutics and new therapeutic platforms, giving founders several different routes to early-stage capital.

DealBio selected nine investors to feature based on recent, relevant healthtech activity in France. The list is not a ranking.

Sofinnova Partners

European life-sciences investor with dedicated strategies spanning biotech, medical devices and digital medicine.

Stage
Seed · Series A
Sector / Focus
Biotech · Medtech · Digital Medicine
Investment markets
France · Europe
Investor type
VC

Relevant investment

Sofinnova Partners has backed Paris-based BrightHeart from seed and participated in its €11 million Series A in January 2026. BrightHeart applies AI to prenatal ultrasound to help clinicians assess fetal-heart views and identify signs of severe congenital heart defects. Sofinnova also participated in One Biosciences’ €15 million Series A in 2025, adding exposure to clinical single-cell tumour profiling.

Elaia

European VC investing in deep technology and science-led startups.

Stage
Seed
Sector / Focus
Deep Tech · Biotech · Healthtech
Investment markets
France · Europe
Investor type
VC

Relevant investment

Elaia co-led Paris-based Enodia Therapeutics’ €20.7 million seed round in January 2026. Enodia combines , machine learning and small-molecule discovery to target disease-related proteins at the point of synthesis, initially across immune-inflammatory disease and oncology.

Bpifrance

French public investment institution supporting innovation through equity, loans and specialist investment strategies.

Stage
Seed · Series A
Sector / Focus
Health · Deep Tech · Biotech
Investment markets
France
Investor type
Public Investor

Relevant investment

Bpifrance co-led Enodia Therapeutics’ €20.7 million seed financing through its InnoBio strategy. The deal illustrates Bpifrance’s role as a direct equity investor in science-led French health startups rather than only a provider of grants or debt.

XAnge

European VC investing in technology and impact, including digital health.

Stage
Seed
Sector / Focus
Digital Health · Impact · Technology
Investment markets
France
Investor type
VC

Relevant investment

Through Mutuelles Impact, which it manages, XAnge backed Lyv Healthcare’s €2.6 million seed round in 2025. Lyv develops a for endometriosis, combining personalised non-drug interventions with ongoing medical care.

Ring Capital

French VC investing in technology companies with impact and category-building potential.

Stage
Seed · Series A
Sector / Focus
Digital Health · Diagnostics · Impact
Investment markets
France
Investor type
VC

Relevant investment

Ring Capital participated in En Carta Diagnostics’ €5 million financing in 2026. En Carta is developing a molecular platform designed to deliver laboratory-grade results in around 30 minutes, starting with early Lyme disease detection. The round is intended to support regulatory certification, industrialisation and commercial launch.

GO CAPITAL

French early-stage investor backing innovation-led companies in healthcare and other technology sectors.

Stage
Seed · Series A
Sector / Focus
Deep Tech · Healthtech · Medtech
Investment markets
France
Investor type
VC

Relevant investment

GO CAPITAL co-led BrightHeart’s €11 million Series A in January 2026. BrightHeart’s B-Right platform is designed to integrate into prenatal ultrasound workflows, checking scan completeness and using AI to support detection of severe fetal-heart abnormalities.

Kima Ventures

Early-stage technology investor backing startups in France and internationally.

Stage
Seed · Series A
Sector / Focus
Technology · Healthtech · Diagnostics
Investment markets
France · Europe
Investor type
VC

Relevant investment

Kima Ventures participated in One Biosciences’ €15 million Series A in July 2025. One Biosciences is developing clinical-grade single-cell tumour profiling that combines data and AI to support treatment decisions, patient selection and drug development.

Impact Shakers

Impact investor and venture platform focused on inclusive entrepreneurship and measurable social outcomes.

Stage
Seed
Sector / Focus
Impact · Digital Health · Inclusive Entrepreneurship
Investment markets
France
Investor type
Impact Investor

Relevant investment

Impact Shakers led Solence’s €1.6 million seed round in 2025 and described it as its first FemTech investment. Solence provides digital support for women with , combining lifestyle guidance, symptom tracking and access to care.

50 Partners

French startup platform and investment network whose 50 Partners Health vertical focuses on healthcare supporting e-health, medtech and biotech startups.

Stage
Seed
Sector / Focus
Digital Health · Medtech · Biotech
Investment markets
France
Investor type
Investor / Accelerator

Relevant investment

Through 50 Partners Health, 50 Partners is an existing investor in En Carta Diagnostics and participated in its €5 million 2026 financing. It has supported the startup since 2022 as En Carta developed a point-of-care molecular diagnostic platform for Lyme disease and other infections, including support around regulatory, industrial and commercial milestones.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.